Compare Adaptive Biotechnologies Corp (ADPT) vs Redwire Corporation (RDW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Redwire Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $20.06 (market cap $3.33B), while Redwire Corporation trades at $10.37 (market cap $2.03B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals.
| ADPT | RDW | |
|---|---|---|
Market Cap | $3.33B | $2.03B |
Sector | Health | Technology |
52-Week High | $22.37 | $25.90 |
52-Week Low | $10.24 | $5.06 |
Enterprise Value | $3.19B | $2.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
RDW trades at $11.36, up 0.44% on the day, amid a bearish technical trend and weak fundamentals. The company reported a net loss of $226.55M in 2025 with a -80.9% net income margin, though revenue grew to $335.38M. Recent news highlights volatility driven by SpaceX's IPO impact and a new defense contract, while analyst consensus remains bullish with an $19.00 price target.
The outlook is challenged by persistent losses and cash burn, but strong analyst buy ratings and contract wins offer potential upside. Key risks include dilution from equity offerings, intense space sector competition, and reliance on financing to fund operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
